Cisplatin

ID: ALA11359

Chembl Id: CHEMBL11359

Max Phase: Approved

First Approval: 1978

Molecular Formula: H6Cl2N2Pt+2

Molecular Weight: 300.05

Molecule Type: Small molecule

Alternative Forms

1. Parent:

   

   ALA11359

   CISPLATIN

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: Yes

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: Yes

Chirality: Yes

Availability: Yes

Prodrug: No

Calculated Properties

Molecular Weight: 300.05

Molecular Weight (Monoisotopic): 298.9545

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Ryu CK, Lee IK, Jung SH, Lee CO..  (1999)  Synthesis and cytotoxic activities of 6-chloro-7-arylamino-5,8-isoquinolinediones.,  9  (8): [PMID:10328288] [10.1016/s0960-894x(99)00152-3]

2. Fenton RR, Easdale WJ, Er HM, O'Mara SM, McKeage MJ, Russell PJ, Hambley TW..  (1997)  Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer.,  40  (7): [PMID:9089330] [10.1021/jm9607966]

3. Hollis LS, Miller AV, Amundsen AR, Schurig JE, Stern EW..  (1990)  cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents.,  33  (1): [PMID:2296007] [10.1021/jm00163a018]

4. Khokhar AR, al-Baker S, Shamsuddin S, Siddik ZH..  (1997)  Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.,  40  (1): [PMID:9016335] [10.1021/jm960587l]

5. Komeda S, Kalayda GV, Lutz M, Spek AL, Yamanaka Y, Sato T, Chikuma M, Reedijk J..  (2003)  New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin.,  46  (7): [PMID:12646031] [10.1021/jm020004+]

6. Wappes B, Jennerwein M, von Angerer E, Schönenberger H, Engel J, Berger M, Wrobel KH..  (1984)  Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma.,  27  (10): [PMID:6481764] [10.1021/jm00376a009]

7. Witiak DT, Rotella DP, Filppi JA, Gallucci J..  (1987)  Stereocontrolled syntheses for the six diastereomeric 1,2-dihydroxy-4,5-diaminocyclohexanes: PtII complexes and P-388 antitumor properties.,  30  (8): [PMID:3612684] [10.1021/jm00391a011]

8. Hollis LS, Amundsen AR, Stern EW..  (1989)  Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+.,  32  (1): [PMID:2909724] [10.1021/jm00121a024]

9. Berners-Price SJ, Girard GR, Hill DT, Sutton BM, Jarrett PS, Faucette LF, Johnson RK, Mirabelli CK, Sadler PJ..  (1990)  Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates.,  33  (5): [PMID:2329559] [10.1021/jm00167a017]

10. Quiroga AG, Pérez JM, López-Solera I, Masaguer JR, Luque A, Román P, Edwards A, Alonso C, Navarro-Ranninger C..  (1998)  Novel tetranuclear orthometalated complexes of Pd(II) and Pt(II) derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxic activity in cis-DDP resistant tumor cell lines. Interaction of these complexes with DNA.,  41  (9): [PMID:9554873] [10.1021/jm970520d]

11. Neidle S, Kelland L, Trent J, Simpson I, Boykin D, Kumar A, Wilson W.  (1997)  Cytotoxicity of bis(phenylamidinium)furan alkyl derivatives in human tumour cell lines: Relation to DNA minor groove binding,  7  (11): [10.1016/S0960-894X(97)00229-1]

12. Fukuda Y, Furuta H, Kusama Y, Ebisu H, Oomori Y, Terashima S..  (1999)  Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.,  42  (8): [PMID:10212131] [10.1021/jm980668c]

13. Kim DK, Kim G, Gam J, Cho YB, Kim HT, Tai JH, Kim KH, Hong WS, Park JG..  (1994)  Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.,  37  (10): [PMID:8182706] [10.1021/jm00036a013]

14. Banik I, Becker FF, Banik BK..  (2003)  Stereoselective synthesis of beta-lactams with polyaromatic imines: entry to new and novel anticancer agents.,  46  (1): [PMID:12502355] [10.1021/jm0255825]

15. Ryu CK, Kang HY, Yi YJ, Shin KH, Lee BH..  (2000)  Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.,  10  (14): [PMID:10915058] [10.1016/s0960-894x(00)00301-2]

16. Marcon G, Carotti S, Coronnello M, Messori L, Mini E, Orioli P, Mazzei T, Cinellu MA, Minghetti G..  (2002)  Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.,  45  (8): [PMID:11931621] [10.1021/jm010997w]

17. Witiak DT, Kamat PL, Allison DL, Liebowitz SM, Glaser R, Holliday JE, Moeschberger ML, Schaller JP..  (1983)  Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.,  26  (12): [PMID:6685770] [10.1021/jm00366a004]

18. Hotze AC, Bacac M, Velders AH, Jansen BA, Kooijman H, Spek AL, Haasnoot JG, Reedijk J..  (2003)  New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.,  46  (9): [PMID:12699392] [10.1021/jm021110e]

19. Hazeldine ST, Polin L, Kushner J, Paluch J, White K, Edelstein M, Palomino E, Corbett TH, Horwitz JP..  (2001)  Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).,  44  (11): [PMID:11356111] [10.1021/jm0005149]

20. Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, Navarro-Ranninger C..  (2002)  Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.,  45  (9): [PMID:11960495] [10.1021/jm010968l]

21. Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH..  (2004)  Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.,  47  (7): [PMID:15027879] [10.1021/jm031070u]

22. Kim DH, Chung SJ, Yeon SW.  (1995)  3-Fluoro-2-(4-methylpiperazin-1-yl)-5,12-dihydro-5-oxobenzoxazolo[3,2-a]quinoline-6-carboxylic acid: Synthesis and In vitro cytotoxic activity,  5  (17): [10.1016/0960-894X(95)00338-T]

23. Shirai R, Takayama H, Nishikawa A, Koiso Y, Hashimoto Y..  (1998)  Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells.,  8  (15): [PMID:9873473] [10.1016/s0960-894x(98)00344-8]

24. Bitha P, Carvajal SG, Citarella RV, Child RG, Delos Santos EF, Dunne TS, Durr FE, Hlavka JJ, Lang SA, Lindsay HL..  (1989)  Water-soluble third generation antitumor platinum complexes, [2,2-bis (aminomethyl)-1,3-propanediol-N,N']-[1,1-cyclobutanedicarboxylato (2-)-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'] [tetrahydro-4H-pyran-4,4-dimethanamine-N,N']platinum(II).,  32  (8): [PMID:2754720] [10.1021/jm00128a052]

25. Bitha P, Carvajal SG, Citarella RV, Delos Santos EF, Durr FE, Hlavka JJ, Lang SA, Lindsay HL, Thomas JP, Wallace RE..  (1989)  A new family of water-soluble, third generation antitumor platinum complexes.,  32  (9): [PMID:2671371] [10.1021/jm00129a008]

26. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X..  (2001)  Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.,  44  (13): [PMID:11405643] [10.1021/jm000476t]

27. Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K..  (2004)  Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.,  47  (8): [PMID:15056007] [10.1021/jm0304966]

28. Middel O, Woerdenbag HJ, van Uden W, van Oeveren A, Jansen JF, Feringa BL, Konings AW, Pras N, Kellogg RM..  (1995)  Synthesis and cytotoxicity of novel lignans.,  38  (12): [PMID:7783142] [10.1021/jm00012a010]

29. Knebel NG, von Angerer E..  (1991)  2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.,  34  (7): [PMID:2066987] [10.1021/jm00111a033]

30. Witiak DT, Rotella DP, Wei Y, Filppi JA, Gallucci JC..  (1989)  Synthesis and P-388 antitumor properties of the four diastereomeric 1-hydroxy-3,4-diaminocyclohexane-Cl2PtII complexes.,  32  (1): [PMID:2909734] [10.1021/jm00121a038]

31. Farrell N, Qu Y, Hacker MP..  (1990)  Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes.,  33  (8): [PMID:2374143] [10.1021/jm00170a021]

32. Farrell N, Qu Y, Hacker MP..  (1990)  Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes.,  33  (8): [PMID:2374143] [10.1021/jm00170a021]

33. Peritz A, al-Baker S, Vollano JF, Schurig JE, Bradner WT, Dabrowiak JC..  (1990)  Antitumor and DNA-binding properties of a group of oligomeric complexes of Pt(II) and Pt(IV).,  33  (8): [PMID:2374144] [10.1021/jm00170a022]

34. He Y, Groleau S, -Gaudreault R, Caron M, Therien H, Berube G.  (1995)  Synthesis and in vitro biological evaluation of new triphenylethylene platinum (II) complexes,  5  (19): [10.1016/0960-894X(95)00381-3]

35. Farrell N, Ha TT, Souchard JP, Wimmer FL, Cros S, Johnson NP..  (1989)  Cytostatic trans-platinum(II) complexes.,  32  (10): [PMID:2795596] [10.1021/jm00130a002]

36. Friebolin W, Schilling G, Zöller M, Amtmann E..  (2004)  Synthesis and structure-activity relationship of novel antitumoral platinum xanthate complexes.,  47  (9): [PMID:15084124] [10.1021/jm0309405]

37. Hodgkinson TJ, Kelland LR, Shipman M, Suzenet F..  (2000)  Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit.,  10  (3): [PMID:10698444] [10.1016/s0960-894x(99)00663-0]

38. Pérez JM, Montero EI, González AM, Solans X, Font-Bardia M, Fuertes MA, Alonso C, Navarro-Ranninger C..  (2000)  X-Ray structure of cytotoxic trans-[PtCl(2)(dimethylamine)(isopropylamine)]: interstrand cross-link efficiency, DNA sequence specificity, and inhibition of the B-Z transition.,  43  (12): [PMID:10882368] [10.1021/jm000925p]

39. Jansen BA, van der Zwan J, den Dulk H, Brouwer J, Reedijk J..  (2001)  Dinuclear alkyldiamine platinum antitumor compounds: a structure-activity relationship study.,  44  (2): [PMID:11170634] [10.1021/jm0010163]

40. Antonini I, Polucci P, Kelland LR, Menta E, Pescalli N, Martelli S..  (1999)  2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.,  42  (14): [PMID:10411474] [10.1021/jm9805586]

41. Gust R, Burgemeister T, Mannschreck A, Schönenberger H..  (1990)  Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine](sulfato)platinum-(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties.,  33  (9): [PMID:2391694] [10.1021/jm00171a031]

42. Beria I, Baraldi PG, Cozzi P, Caldarelli M, Geroni C, Marchini S, Mongelli N, Romagnoli R..  (2004)  Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.,  47  (10): [PMID:15115402] [10.1021/jm031051k]

43. Hoeschele JD, Showalter HD, Kraker AJ, Elliott WL, Roberts BJ, Kampf JW..  (1994)  Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.,  37  (17): [PMID:8064793] [10.1021/jm00043a003]

44. Wang TC, Lee KH, Chen YL, Liou SS, Tzeng CC..  (1998)  Synthesis and anticancer evaluation of certain gamma-aryloxymethyl-alpha-methylene-gamma-phenyl-gamma-butyrolactones.,  8  (19): [PMID:9873620] [10.1016/s0960-894x(98)00487-9]

45. Deng L, Wu H, Yu B, Jiang M, Wu J..  (2004)  Synthesis of OSW-1 analogs with modified side chains and their antitumor activities.,  14  (11): [PMID:15125932] [10.1016/j.bmcl.2004.03.081]

46. Kim YS, Song R, Lee CO, Sohn YS..  (2004)  Synthesis and biological activity of novel platinum(II) complexes of glutamate tethered to hydrophilic hematoporphyrin derivatives.,  14  (11): [PMID:15125953] [10.1016/j.bmcl.2004.03.038]

47. Teixeira LJ, Seabra M, Reis E, da Cruz MT, de Lima MC, Pereira E, Miranda MA, Marques MP..  (2004)  Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates.,  47  (11): [PMID:15139770] [10.1021/jm0311238]

48. Cai L, Lim K, Ren S, Cadena RS, Beck WT..  (2001)  Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexes.,  44  (18): [PMID:11520204] [10.1021/jm0002937]

49. Lee HH, Palmer BD, Baguley BC, Chin M, McFadyen WD, Wickham G, Thorsbourne-Palmer D, Wakelin LP, Denny WA..  (1992)  DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II).,  35  (16): [PMID:1501223] [10.1021/jm00094a008]

50. Palmer BD, Lee HH, Johnson P, Baguley BC, Wickham G, Wakelin LP, McFadyen WD, Denny WA..  (1990)  DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine.,  33  (11): [PMID:2231598] [10.1021/jm00173a015]

51. Kelland LR, Barnard CF, Evans IG, Murrer BA, Theobald BR, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A..  (1995)  Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.,  38  (16): [PMID:7636864] [10.1021/jm00016a004]

52. Mikata Y, Shinohara Y, Yoneda K, Nakamura Y, Brudziñska I, Tanase T, Kitayama T, Takagi R, Okamoto T, Kinoshita I, Doe M, Orvig C, Yano S..  (2001)  Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes.,  11  (23): [PMID:11714607] [10.1016/s0960-894x(01)00623-0]

53. Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T..  (1998)  Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues.,  8  (22): [PMID:9873694] [10.1016/s0960-894x(98)00579-4]

54. Lowe G, Droz AS, Vilaivan T, Weaver GW, Park JJ, Pratt JM, Tweedale L, Kelland LR..  (1999)  Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma.,  42  (16): [PMID:10447962] [10.1021/jm991053y]

55. Qu Y, Rauter H, Soares Fontes AP, Bandarage R, Kelland LR, Farrell N..  (2000)  Synthesis, characterization, and cytotoxicity of trifunctional dinuclear platinum complexes: comparison of effects of geometry and polyfunctionality on biological activity.,  43  (16): [PMID:10956227] [10.1021/jm990536z]

56. Tsuzuki Y, Tomita K, Sato Y, Kashimoto S, Chiba K..  (2004)  Synthesis and structure-activity relationships of 3-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines as novel antitumor agents.,  14  (12): [PMID:15149673] [10.1016/j.bmcl.2004.04.011]

57. Opsenica D, Pocsfalvi G, Juranic Z, Tinant B, Declercq JP, Kyle DE, Milhous WK, Solaja BA..  (2000)  Cholic acid derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity.,  43  (17): [PMID:10966746] [10.1021/jm000952f]

58. Khokhar AR, al-Baker S, Brown T, Perez-Soler R..  (1991)  Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II) complexes incorporated in liposomes.,  34  (1): [PMID:1992134] [10.1021/jm00105a051]

59. Webster LK, Deacon GB, Buxton DP, Hillcoat BL, James AM, Roos IA, Thomson RJ, Wakelin LP, Williams TL..  (1992)  cis-bis(pyridine)platinum(II) organoamides with unexpected growth inhibition properties and antitumor activity.,  35  (18): [PMID:1527784] [10.1021/jm00096a007]

60. Saczewski F, Reszka P, Gdaniec M, Grünert R, Bednarski PJ..  (2004)  Synthesis, X-ray crystal structures, stabilities, and in vitro cytotoxic activities of new heteroarylacrylonitriles.,  47  (13): [PMID:15189040] [10.1021/jm0311036]

61. von Nussbaum F, Miller B, Wild S, Hilger CS, Schumann S, Zorbas H, Beck W, Steglich W..  (1999)  Synthesis of 1-(2-aminophenyl)isoquinolines and the biological activity of their cis-dichloro platinum(II) complexes.,  42  (18): [PMID:10479280] [10.1021/jm980434t]

62. Geng X, Geney R, Pera P, Bernacki RJ, Ojima I..  (2004)  Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton.,  14  (13): [PMID:15177459] [10.1016/j.bmcl.2004.04.060]

63. Rezler EM, Fenton RR, Esdale WJ, McKeage MJ, Russell PJ, Hambley TW..  (1997)  Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl- and N,N-dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II).,  40  (22): [PMID:9357517] [10.1021/jm960854n]

64. Messori L, Abbate F, Marcon G, Orioli P, Fontani M, Mini E, Mazzei T, Carotti S, O'Connell T, Zanello P..  (2000)  Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds.,  43  (19): [PMID:11000008] [10.1021/jm990492u]

65. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M..  (2003)  Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.,  46  (16): [PMID:12877593] [10.1021/jm030785u]

66. Selassie CD, Hansch C, Khwaja TA, Dias CB, Pentecost S..  (1984)  Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.,  27  (3): [PMID:6699880] [10.1021/jm00369a019]

67. Morris RE, Aird RE, Murdoch Pdel S, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI, Sadler PJ..  (2001)  Inhibition of cancer cell growth by ruthenium(II) arene complexes.,  44  (22): [PMID:11606126] [10.1021/jm010051m]

68. Anderson WK, Kasliwal R, Houston DM, Wang YS, Narayanan VL, Haugwitz RD, Plowman J..  (1995)  Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines.,  38  (19): [PMID:7562909] [10.1021/jm00019a008]

69. Navarro-Ranninger C, López-Solera I, Pérez JM, Rodríguez J, García-Ruano JL, Raithby PR, Masaguer JR, Alonso C..  (1993)  Analysis of two cycloplatinated compounds derived from N-(4-methoxyphenyl)-alpha-benzoylbenzylidenamine. Comparison of the activity of these compounds with other isostructural cyclopalladated compounds.,  36  (24): [PMID:8254608] [10.1021/jm00076a006]

70. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ..  (1996)  Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.,  39  (20): [PMID:8831755] [10.1021/jm9604080]

71. Descôteaux C, Provencher-Mandeville J, Mathieu I, Perron V, Mandal SK, Asselin E, Bérubé G..  (2003)  Synthesis of 17beta-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines.,  13  (22): [PMID:14592477] [10.1016/j.bmcl.2003.09.011]

72. Wilson SC, Howard PW, Forrow SM, Hartley JA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE..  (1999)  Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.,  42  (20): [PMID:10514273] [10.1021/jm981124d]

73. Cheng CC, Dong Q, Liu DF, Luo YL, Liu LF, Chen AY, Yu C, Savaraj N, Chou TC..  (1993)  Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.,  36  (25): [PMID:8258835] [10.1021/jm00077a016]

74. Gibson D, Gean KF, Ben-Shoshan R, Ramu A, Ringel I, Katzhendler J..  (1991)  Preparation, characterization, and anticancer activity of a series of cis-PtCl2 complexes linked to anthraquinone intercalators.,  34  (1): [PMID:1992142] [10.1021/jm00105a063]

75. Montero EI, Díaz S, González-Vadillo AM, Pérez JM, Alonso C, Navarro-Ranninger C..  (1999)  Preparation and characterization of novel trans-[PtCl(2)(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells.,  42  (20): [PMID:10514297] [10.1021/jm991015e]

76. Maeda M, Abiko N, Uchida H, Sasaki T..  (1984)  Synthesis and antitumor activity of cis-dichloroplatinum (II)-N-aminated nucleoside complexes.,  27  (4): [PMID:6538600] [10.1021/jm00370a006]

77. Kraker AJ, Hoeschele JD, Elliott WL, Showalter HD, Sercel AD, Farrell NP..  (1992)  Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.,  35  (24): [PMID:1335074] [10.1021/jm00102a003]

78. Hansch C, Venger BH, Panthananickal A..  (1980)  Mutagenicity of substituted (o-phenylenediamine)platinum dichloride in the Ames test. A quantitative structure-activity analysis.,  23  (4): [PMID:6991694] [10.1021/jm00178a019]

79. Ryu CK, Kang HY, Lee SK, Nam KA, Hong CY, Ko WG, Lee BH..  (2000)  5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.,  10  (5): [PMID:10743948] [10.1016/s0960-894x(00)00014-7]

80. Okada T, El-Mehasseb IM, Kodaka M, Tomohiro T, Okamoto K, Okuno H..  (2001)  Mononuclear platinum(II) complex with 2-phenylpyridine ligands showing high cytotoxicity against mouse sarcoma 180 cells acquiring high cisplatin resistance.,  44  (26): [PMID:11741483] [10.1021/jm010203d]

81. Yoo HW, Suh ME, Park SW..  (1998)  Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.,  41  (24): [PMID:9822542] [10.1021/jm970695n]

82. Platts JA, Hibbs DE, Hambley TW, Hall MD..  (2001)  Calculation of the hydrophobicity of platinum drugs.,  44  (3): [PMID:11462986] [10.1021/jm001080k]

83. Antonini I, Polucci P, Kelland LR, Spinelli S, Pescalli N, Martelli S..  (2000)  N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.,  43  (25): [PMID:11123989] [10.1021/jm000131a]

84. Yamazaki Y, Goto M, Kobayashi K, Ogawa Y, Shimura T, Oka S, Okuno H.  (1994)  Antiproliferative activity of haloosmocenium ions against human and murine cancer cell lines,  4  (3): [10.1016/0960-894X(94)80021-9]

85. Galanski M, Slaby S, Jakupec MA, Keppler BK..  (2003)  Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-bis(phosphonomethyl)glycine ligand.,  46  (23): [PMID:14584945] [10.1021/jm0308040]

86. Sawanishi H, Wakusawa S, Murakami R, Muramatsu H, Suzuki H, Takashima A, Aizawa T, Miyamoto K..  (1995)  Novel inhibitors for multidrug resistance: 1,3,5-triazacycloheptanes.,  38  (26): [PMID:8544183] [10.1021/jm00026a014]

87. Coluccia M, Nassi A, Loseto F, Boccarelli A, Mariggio MA, Giordano D, Intini FP, Caputo P, Natile G..  (1993)  A trans-platinum complex showing higher antitumor activity than the cis congeners.,  36  (4): [PMID:8474104] [10.1021/jm00056a012]

88. Noji M, Okamoto K, Kidani Y, Tashiro T..  (1981)  Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388.,  24  (5): [PMID:7241508] [10.1021/jm00137a007]

89. Noji M, Okamoto K, Kidani Y, Tashiro T..  (1981)  Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388.,  24  (5): [PMID:7241508] [10.1021/jm00137a007]

90. Rekonen P, Dohta Y, Kodaka M, Okada T, Okamoto K, Okuno H..  (1997)  Cytotoxicity of platinum (II) dinuclear complexes with 1-alkylthymine ligands against mouse sarcoma 180 cells.,  40  (4): [PMID:9046342] [10.1021/jm960633h]

91. Najajreh Y, Perez JM, Navarro-Ranninger C, Gibson D..  (2002)  Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines.,  45  (24): [PMID:12431046] [10.1021/jm0201969]

92. Khazanov E, Barenholz Y, Gibson D, Najajreh Y..  (2002)  Novel apoptosis-inducing trans-platinum piperidine derivatives: synthesis and biological characterization.,  45  (24): [PMID:12431047] [10.1021/jm020817y]

93. Buckley RG, Elsome AM, Fricker SP, Henderson GR, Theobald BR, Parish RV, Howe BP, Kelland LR..  (1996)  Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.,  39  (26): [PMID:8978849] [10.1021/jm9601563]

94. Pérez JM, López-Solera I, Montero EI, Brana MF, Alonso C, Robinson SP, Navarro-Ranninger C..  (1999)  Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes.,  42  (26): [PMID:10639290] [10.1021/jm991099r]

95. Tomita K, Tsuzuki Y, Shibamori K, Tashima M, Kajikawa F, Sato Y, Kashimoto S, Chiba K, Hino K..  (2002)  Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1.,  45  (25): [PMID:12459024] [10.1021/jm010057b]

96. Mimaki Y, Kuroda M, Kameyama A, Sashida Y, Hirano T, Oka K, Maekawa R, Wada T, Sugita K, Beutler JA.  (1997)  Cholestane glycosides with potent cytostatic activities on various tumor cells from Ornithogalum saundersiae bulbs,  7  (5): [10.1016/S0960-894X(97)00071-1]

97. Samuel PM, de Vos D, Raveendra D, Sarma JA, Roy S..  (2002)  3-D QSAR studies on new dibenzyltin(IV) anticancer agents by comparative molecular field analysis (CoMFA).,  12  (1): [PMID:11738573] [10.1016/s0960-894x(01)00684-9]

98. Kim D, Kim Y, Kim H, Kim KH.  (1996)  Synthesis and in vitro cytotoxicity of cis-dichloro[(2S,3R,4S)-2-aminomethyl-3,4-(O-isopropylidene)dihydroxy- or -3,4-dihydroxypyrrolidine]platinum(II),  6  (6): [10.1016/0960-894X(96)00088-1]

99. Kim D, Gam J, Cho Y, Kim H, Kim KH.  (1996)  Synthesis and antitumor activity of (2R,3R)-2,3-dihydroxy- and -2,3-dialkoxy-1,4-diaminobutane platinum(II) complexes,  6  (6): [10.1016/0960-894X(96)00089-3]

100. Lin TS, Zhou RX, Scanlon KJ, Brubaker WF, Lee JJ, Woods K, Humphreys C, Prusoff WH..  (1986)  Synthesis and biological activity of several amino nucleoside-platinum(II) complexes.,  29  (5): [PMID:3701784] [10.1021/jm00155a017]

101. Vollano JF, Al-Baker S, Dabrowiak JC, Schurig JE..  (1987)  Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane.,  30  (4): [PMID:3560163] [10.1021/jm00387a023]

102. Haines AH, Morley C, Murrer BA..  (1989)  Analogues of cisplatin derived from diaminodideoxytetritols. Synthesis and activity against the ADJ/PC6 plasmacytoma in mice.,  32  (4): [PMID:2704024] [10.1021/jm00124a004]

103. Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE..  (2001)  Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.,  44  (5): [PMID:11262084] [10.1021/jm001064n]

104. Zák F, Turánek J, Kroutil A, Sova P, Mistr A, Poulová A, Mikolin P, Zák Z, Kasná A, Záluská D, Neca J, Sindlerová L, Kozubík A..  (2004)  Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.,  47  (3): [PMID:14736257] [10.1021/jm030858+]

105. Kim D, Gam J, Kim H, Kim KH.  (1996)  Synthesis and in vitro cytotoxicity of cis-(glycolato-O,O)-[2-substituted-(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane]platinum (II),  6  (7): [10.1016/0960-894X(96)00126-6]

106. Karl J, Gust R, Spruss T, Schneider MR, Schönenberger H, Engel J, Wrobel KH, Lux F, Haeberlin ST..  (1988)  Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.,  31  (1): [PMID:3336035] [10.1021/jm00396a012]

107. Souchard JP, Ha TT, Cros S, Johnson NP..  (1991)  Hydrophobicity parameters for platinum complexes.,  34  (2): [PMID:1995911] [10.1021/jm00106a056]

108. Brandon RJ, Dabrowiak JC..  (1984)  Synthesis, characterization, and properties of a group of platinum (IV) complexes.,  27  (7): [PMID:6330359] [10.1021/jm00373a009]

109. Kim D, Gam J, Kim KH.  (1994)  Synthesis and in vitro cytotoxicity of 1,3-dioxolane-2-(2-ethanamine)-2-methanamine platinum(II) complexes,  4  (7): [10.1016/S0960-894X(01)80262-6]

110. Schnur RC, Fliri AF, Kajiji S, Pollack VA..  (1991)  N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis lung carcinoma.,  34  (3): [PMID:2002471] [10.1021/jm00107a007]

111. Ott I, Schmidt K, Kircher B, Schumacher P, Wiglenda T, Gust R..  (2005)  Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.,  48  (2): [PMID:15658875] [10.1021/jm049326z]

112. Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D..  (2005)  Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes.,  48  (5): [PMID:15743200] [10.1021/jm049191x]

113. Monti E, Gariboldi M, Maiocchi A, Marengo E, Cassino C, Gabano E, Osella D..  (2005)  Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach.,  48  (3): [PMID:15689170] [10.1021/jm049508t]

114. Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG, Denny WA, Gordon KA, Gustin D, Haugen J, Kline T, Nguyen MT, Senter PD..  (2005)  Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.,  48  (5): [PMID:15743178] [10.1021/jm040137q]

115. Wang L, Gou S, Chen Y, Liu Y..  (2005)  Potential new antitumor agents from an innovative combination of camphorato, a ramification of traditional Chinese medicine, with a platinum moiety.,  15  (14): [PMID:15953727] [10.1016/j.bmcl.2005.05.025]

116. Hess SM, Anderson JG, Bierbach U..  (2005)  A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells.,  15  (2): [PMID:15603970] [10.1016/j.bmcl.2004.10.049]

117. Gagnon V, St-Germain ME, Descôteaux C, Provencher-Mandeville J, Parent S, Mandal SK, Asselin E, Bérubé G..  (2004)  Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies.,  14  (23): [PMID:15501069] [10.1016/j.bmcl.2004.09.015]

118. Kim JK, Toti US, Song R, Sohn YS..  (2005)  A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide.,  15  (15): [PMID:15982876] [10.1016/j.bmcl.2005.05.057]

119. Kalayda GV, Zhang G, Abraham T, Tanke HJ, Reedijk J..  (2005)  Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs.,  48  (16): [PMID:16078838] [10.1021/jm050216h]

120. Park HJ, Lee K, Park SJ, Ahn B, Lee JC, Cho H, Lee KI..  (2005)  Identification of antitumor activity of pyrazole oxime ethers.,  15  (13): [PMID:15922597] [10.1016/j.bmcl.2005.03.082]

121. Ma ES, Bates WD, Edmunds A, Kelland LR, Fojo T, Farrell N..  (2005)  Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile.,  48  (18): [PMID:16134932] [10.1021/jm050539d]

122. Ren Y, Zhang H, Huang J..  (2005)  Synthesis and cytotoxic activity of platinum complex immobilized by branched polyethylene glycol.,  15  (20): [PMID:16085413] [10.1016/j.bmcl.2005.07.019]

123. Xiong Y, Wang K, Pan Y, Sun H, Tu J..  (2006)  Isolation, synthesis, and anti-tumor activities of a novel class of podocarpic diterpenes.,  16  (4): [PMID:16309905] [10.1016/j.bmcl.2005.11.023]

124. Ishar MP, Singh G, Singh S, Sreenivasan KK, Singh G..  (2006)  Design, synthesis, and evaluation of novel 6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents.,  16  (5): [PMID:16332438] [10.1016/j.bmcl.2005.11.044]

125. PubChem BioAssay data set, 

126. PubChem BioAssay data set, 

127. PubChem BioAssay data set, 

128. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ..  (2010)  Developing structure-activity relationships for the prediction of hepatotoxicity.,  23  (7): [PMID:20553011] [10.1021/tx1000865]

129. Ekins S, Williams AJ, Xu JJ..  (2010)  A predictive ligand-based Bayesian model for human drug-induced liver injury.,  38  (12): [PMID:20843939] [10.1124/dmd.110.035113]

130. Unpublished dataset, 

131. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

132. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W..  (2011)  FDA-approved drug labeling for the study of drug-induced liver injury.,  16  (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007]

133. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

134. PubChem BioAssay data set, 

135. PubChem BioAssay data set, 

136. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA..  (1999)  A transfected cell model for the renal toxin transporter, rOCT2.,  47  (1): [PMID:10220855] [10.1093/toxsci/47.2.181]

137. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK..  (2004)  Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells.,  50  (1): [PMID:15211078] [10.1159/000077803]

138. Demeule M, Brossard M, Béliveau R..  (1999)  Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter.,  277  (1): [PMID:10600929] [10.1152/ajprenal.1999.277.6.f832]

139. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM..  (2001)  Up-regulation of transporters of the MRP family by drugs and toxins.,  120  (1): [PMID:11323161] [10.1016/s0378-4274(01)00306-x]

140. Li D, Jang SH, Kim J, Wientjes MG, Au JL..  (2003)  Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents.,  20  (1): [PMID:12608535] [10.1023/a:1022242607418]

141. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD..  (2002)  Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).,  62  (1): [PMID:12414644]

142. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

143. PubChem BioAssay data set, 

144. PubChem BioAssay data set, 

145. Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute,  [10.6019/CHEMBL1201861]

146. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP..  (2013)  Structure-based identification of OATP1B1/3 inhibitors.,  83  (6): [PMID:23571415] [10.1124/mol.112.084152]

147. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R..  (2004)  [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].,  28  (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2]

148. PubChem BioAssay data set, 

149. PubChem BioAssay data set, 

150. WHO Anatomical Therapeutic Chemical Classification, 

151. British National Formulary (72nd edition), 

152. Open TG-GATES,  [10.6019/CHEMBL3885861]

153. DrugMatrix,  [10.6019/CHEMBL3885881]

154. Unpublished dataset, 

155. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

156. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

157. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

Source

Source(12):

• Scientific Literature
• Sanger Institute Genomics of Drug Sensitivity in Cancer
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• Open TG-GATEs
• USP Dictionary of USAN and International Drug Names
• DrugMatrix
• TP-search Transporter Database
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21